RS130-180, also known as N-(2-propargyloxy)-2,5-dimethoxy-4-(dimethylamino)phenethylamine, is a β-arrestin-biased serotonin 5-HT2A receptor agonist of the phenethylamine, 2C, and NBOMe families. It is the NBOMe derivative in which the phenyl ring has an N,N-dimethylamino substitution at the 4 position and the 2-position methoxy group on the benzyl ring has been replaced with a propynyloxy group. The drug favors activation of β-arrestin signaling over Gq signaling. RS130-180 is said to be useful for in-vitro studies, but to have suboptimal pharmacokinetic properties for in-vivo use. β-Arrestin-biased serotonin 5-HT2A receptor agonists do not produce the head-twitch response in rodents and it is thought that they may be non-hallucinogenic in humans. The cryo-EM structures of the serotonin 5-HT2A receptor with RS130-180, as well as with various serotonergic psychedelics, have been solved and published by Bryan Roth and colleagues. RS130-180 was first described in the literature by 2022. It was derived from an earlier compound called ZINC000341335936, which was identified via in-silico screening of 1.6 billion molecules for serotonin 5-HT2A receptor agonism with AlphaFold2. RS130-180 was developed via structural modification of ZINC000341335936 by David E. Nichols and colleagues.
See also 25-NB List of miscellaneous 5-HT2A receptor agonists Non-hallucinogenic 5-HT2A receptor agonist 25N-NBOMe 25N-NBPh 25N-N1-Nap 25CN-NBOMe 25CN-NBOH Ultra-large-scale docking
References
External links RS130-180 - Isomer Design



